The dedicated immuno-oncology summit and biomarker discovery conference series, uniting global leaders in San Diego, London and Boston.
For diagnostics, tools, CRO and platform companies
Sponsor or exhibit at ImmunoMark 2027
Pre-scheduled 20-minute 1:1 meetings with IO and biomarker teams. At London 2026, sponsors held 15–25 meetings each.
Three independent editions per year, each tailored to its regional scientific community.
The only conference series dedicated to the intersection of Immuno-Oncology and Biomarker science.
Two fully independent parallel tracks - Immuno-Oncology and Biomarkers & CDx - for in-depth, targeted learning.
45-50% of attendees are C-suite, VPs, and Directors from pharma, biotech, and diagnostics companies globally.
Structured 1:1 meetings, panel discussions, and a Day 1 drinks reception designed for meaningful strategic connections.
San Diego, London and Boston: three of the world's leading centres for oncology drug development and biotech innovation.
Programs bridge bench science with regulatory, clinical, and commercialization strategy - relevant to all stakeholders.
Experts from AstraZeneca, Roche, Merck, J&J, Novartis, GSK, Oxford, and more - setting the scientific standard.
Companies who sponsor ImmunoMark to reach the world's most concentrated audience of oncology decision-makers.
The real London 2026 results, plus profiles of how different types of company use the 1:1 meetings, talks and stand to build pipeline.
ImmunoMark Summit delivers actionable discussions that go beyond theory - bridging clinical research, regulatory strategy, and commercial impact.
Sponsors consistently highlight the quality of speakers, curated networking, and the depth of scientific exchange that sets this summit apart.
300+ senior leaders. Two streams. One agenda: advancing precision oncology.
Waitlist for Boston Edition Register for San Diego Edition Register for London Edition